Tatjana Sarenac Vulovic, Katarina Mirjane Janicijevic


Primary open-angle glaucoma (POAG) is defined as a chronic and progressive disease. Date suggested that it is the second most common cause of the blindness in the world. Blindness, as global problem, is partially consequences of poor health insurance, low medical education, etc. The only modifiable risk factor for glaucoma is intraocular pressure. Cost of the antiglaucomatous treatment increased by prescribing and using wide spectrum of antiglaucomatous drugs. If an ophthalmologist is not satisfied with glaucomatous disease control, need for the laser or surgical treatment is appeared. Disease stadium also determines the cost of the treatment. The social and economic burden of glaucoma can be changed by increased life expectancy, older population age and higher per capita GDP. Unique opinion about cost effectiveness can not be reached because of conflict of different findings in many studies. Treatment approached must be individualized to every patients according to disease’s stadium, available therapeutic modalities, life expectancy and the level of GDP. Efficacy, adherence to treatment and potential side effects of prescribed medication also determine treatment resources.


primary open-angle glaucoma, therapy, pharmacoeconomics, social burden of glaucoma

Full Text:



Shields MB. Textbook of Glaucoma 5th ed. In: Classification of the glaucomas. Baltimore: Lippincott Williams and Wilkins, 2005: 155–62.

Palimkar A, Khandekar R, Venkataraman V. Prevalence and distribution of glaucoma in central India (Glaucoma Survey 2001). Indian J Ophthalmol. 2008;56(1):57–62.

Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–7.

Burr JM, Mowatt G, Hernández R et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(41):1–190.

Chen XY, Cai Y. Epidemiology and classification of primary angle-closure glaucoma today

Zhonghua Yan Ke Za Zhi. 2011;47(10):949-52.

Heijl A, Leske MC, Bengtsson B, et al. Early Manifest Glaucoma Trial Group Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–79.

Bagnis A, Papadia M, Scotto R, Traverso CE. Current and emerging medical therapies in treatment of glaucoma. Expert Opin Emerg Drugs. 2011;16(2):293–307.

National Collaborating Centre for Acute Care (UK) Glaucoma. Diagnosis and Management of Chronic Open Angle Glaucoma and Ocular Hypertension. London: 2009. (Nice Clinical Guidelines, No 85).

Rachmiel R, Trope GE, Chipman ML, Gouws P, Buys YM. Effect of medical therapy on glaucoma filtration surgery rates in Ontario. Arch Ophthalmol. 2006;124(10):1472–7.

Samples JR, Singh K, Lin SC, et al. Laser trabeculoplasty for open angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2011;118(11):2296–302.

Chung PY, Schuman JS, Netland PA, Lloyd-Muhammad RA, Jacobs DS. Five-year results of a randomized, prospective, clinical trial of diode vs argon laser trabeculoplasty for open-angle glaucoma. Am J Ophthalmol. 1998;126(2):185–90.

Bergea B, Bodin L, Svedbergh B. Primary argon laser trabeculoplasty. Long term effects on visual fields. Acta Ophthalmol Scand. 1995;73(3):207–15.

Kim HY, Egbert PR, Singh K. Long-term comparison of primary trabeculectomy with 5-fluorouracil versus mitomycin C in West Africa. J Glaucoma. 2008;17(7):578–83.

Broadway D, Murdoch I. Glaucoma in blacks. In: El Sayyad F, editor. The Refractory Glaucomas. New York: Igaku-Shoin Medical Publishers, 1995: 31–54.

Singh K, Egbert PR, Byrd S, et al. Trabeculectomy with intraoperative 5-fluorouracil vs mitomycin C. Am J Ophthalmol. 1997;123(1):48–53.

Kirwan JF, Cousens S, Venter L, et al. Effect of beta radiation on success of glaucoma drainage surgery in South Africa: randomised controlled trial. BMJ. 2006;333(7575):942.

Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;9:CD004399.

Vasudevan SK, Gupta V, Crowston JG. Neuroprotection in glaucoma. Indian J Ophthalmol. 2011;59:S102–13.

Inoue T, Tanihara H. Rho-associated kinase inhibitors: a novel glaucoma therapy. Prog Retin Eye Res. 2013;37:1–12.

Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci. 2011;88(1):155–63.

Wiafe B. Economics of surgery worldwide: Developing countries. In: Shaarawy T, Sherwood MB, Hitchings RA, Crowston JG, editors. Glaucoma Vol 2: Surgical Management. Philadelphia: Saunder Elsevier, 2009.

Omoti AE. A review of the choice of therapy in primary open angle glaucoma. Niger J Clin Pract. 2005;8(1):29–34.

Omoti AE, Edema OT, Akpe BA, Musa P. Cost analysis of medical versus surgical management of glaucoma in Nigeria. J Ophthalmic Vis Res. 2010;5(4):232–9.

Rahman MQ, Beard SM, Discombe R, Sharma R, Montgomery DM. Direct healthcare costs of glaucoma treatment. Br J Ophthalmol. 2013;97(6):720–4.

Ainsworth JR, Jay JL. Cost analysis of early trabeculectomy versus conventional management in primary open angle glaucoma. Eye (Lond). 1991;5(3):322–8.

Rouland JF, Berdeaux G, Lafuma A. The economic burden of glaucoma and ocular hypertension: implications for patient management: a review. Drugs Aging. 2005;22(4):315–21.

Adio AO, Onua AA. Economic burden of glaucoma in Rivers State, Nigeria. Clin Ophthalmol. 2012;6:2023–31.

WHO. Macroeconomics and Health: Investing in Health for Economic Development. World Health Organisation, Switzerland: [Accessed March 28, 2014]. (Report of Commission of Macroeconomics and Health). Available from

United Nations Development Programme. Human Development Report 2006: Beyond scarcity: Power, poverty and the global water crisis. New York: United Nations Development Programme, 2006. [Accessed March 28, 2014]. Available from

Ramchandani M. Glaucoma in the developing world: The balance between benefits and harms of surgery varies in different settings. BMJ. 2006;333(7575):932.

Tarkkanen A, Kivela T. John G. Lindberg and the discovery of exfoliation syndrome. Acta Ophthalmol Scand. 2002;80(2):151-4.

Quigley H, Buhrmann R, West S, Isseme I, Scudder M, Oliva MS. Long term results of glaucoma surgery among participants in an east African population survey. Br J Ophthalmol. 2000;84(8):860–4.

Rein DB, Wittenborn JS, Lee PP, et al. The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology. 2009;116(5):823-32.

Traverso CE, Walt JG, Kelly SP, et al. Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol. 2005;89(10):1245–9.

Hirsch JD. Considerations in the Pharmacoeconomics of Glaucoma. Manag Care. 2002;11(11 suppl):32–7.

Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton DW. Cost-effectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012;130(4):497–505.

Babighian S, Caretti L, Tavolato M, Cian R, Galan A. Excimer laser trabeculotomy vs 180 degrees selective laser trabeculoplasty in primary open-angle glaucoma. A 2-year randomized, controlled trial. Eye (Lond). 2010;24(4):632–8.

Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics. 2007;25(4):287–308.

Sharma A, Jofre-Bonet M, Panca M, Lawrenson JG, Murdoch I. An economic comparison of hospital-based and community-based glaucoma clinics. Eye (Lond). 2012;26(7):967–71.

Orme M, Collins S, Loftus J. Long-term medical management of primary open-angle glaucoma and ocular hypertension in the UK: optimizing cost-effectiveness and clinic resources by minimizing therapy switches. J Glaucoma. 2012;21(7):433–49.

Gray SF, Spry PG, Brookes ST, et al. The Bristol shared care glaucoma study: outcome at follow up at 2 years. Br J Ophthalmol. 2000;84(5):456–63.

Baudouin C, Renard JP, Nordmann JP, et al. Prevalence and risk factors for ocular surface disease among patients treated over the long term for glaucoma or ocular hypertension. Eur J Ophthalmol. 2013;23(1):47–54.

Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418–23.

Leung EW, Medeiros F, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17(5):350–5.

Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol/ 2010;88(3):329–36.

Odberg T, Jakobsen JE, Hultgren SJ, Halseide R. The impact of glaucoma on the quality of life of patients in Norway. Results from a self-administered questionnaire. Acta Ophthalmol Scand. 2001;79(2):116–20.

Olthoff CM, Schouten JS, Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology. 2005;112(6):953–61.

Mansberger SL, Sheppler CR, McClure TM, et al. Psychometrics of a new questionnaire to assess glaucoma adherence: the Glaucoma Treatment Compliance Assessment Tool (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2013;111:1–16.

Leite MT, Sakata LM, Medeiros FA. Managing glaucoma in developing countries. Arq Bras Oftalmol .2011;74(2):83–4.

Maric V, Markovic V, Bozic M, Marjanovic I. Mistakes in the diagnosis and treatment of primary angle-closure glaucoma: Case report. Sanamed. 2016;11(2):135-40.



  • There are currently no refbacks.

Copyright (c) 2016 SANAMED

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.